|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Denosumab compared with zoledronic acid for the treatment of bone metastases in pa tients with advanced breast cancer: a randomized, double-blind study显示文摘 | Stopeck A T Lipton A Body J J | 2010 | J Clin Oncol2010，28，35： | 1 |
| 2 | Denosumab com- pared with zoledronic acid for the treatment of bone me- tastases in patients with advanced breast cancer: a ran- domized, double-blind study显示文摘 | Stopeck AT Lipton A Body J J | 2010 | J Clin Oneol2010，28，35： | 1 |
| 3 | Superiority of denosumab to zoledronic acid for prevention of skeletal-re- lated events: A combined analysis of 3 pivotal, ran- domised, phase 3 trials显示文摘 | Lipton A Fizazi K Stopeck AT | 2012 | Eur J Cancer2012，48，16： | 1 |
| 4 | Phase Ⅱ trial of the HSP90 inhibitor tanesp imycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)显示文摘 | Modi S Sugarman S Stopeck A | 2008 | J ClinOncol2008，26，5： | 1 |
| 5 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study 显示文摘 | Stopeck AT Lipton A Body JJ | 2010 | J Clin Oncol2010，28，35： | 1 |
| 6 | Pain outcomes in patients with advanced breast cancer and bone metastases:results from a randomized,double-blind study of denosumab and zoledronic acid显示文摘 | Cleeland CS Body JJ Stopeck A | | 0，，04： | 1 |
| 7 | Phase Ⅰ trial of a novel epothilone,KOS-1584,using a weekly dosing schedule显示文摘 | Stopeck A Thomas E Jones S | 2006 | J Clin Oncol2006，24，： | 1 |
| 8 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized,doubleblind study显示文摘 | STOPECK AT LIPTON A BODY JJ | 2010 | J Clin Oncol2010，28，35： | 1 |
| 9 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double- blind study显示文摘 | Stopeck AT Lipton A Body J J | 2010 | J Clin Oncol2010，28，35： | 1 |
| 10 | Phase Ⅱ study of SU5416,a small molecule vascular endo-thelial growth factor tyrosine kinase receptor inhibitor,in patients with refractory multiple myeloma显示文摘 | ZANGARI M ANAISSIE E STOPECK A | 2004 | Clin Cancer Res2004，10，11： | 1 |
| 11 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized,double-blind study 显示文摘 | Stopeck AT Lipton A Body JJ | 2010 | J Clin Oncol2010，28，35： | 1 |
| 12 | HSP90 inhibition iseffective in breast cancer; a phase II trial of tanespimycin ( 17-AAG) plus trastuzumab in patients with HER2-positive metastaticbreast cancer progressing on trastuzumab 显示文摘 | MODI S STOPECK A LINDEN H | 2011 | Clin Cancer Res2011，17，15： | 1 |
| 13 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast eancer:a randomized, double-hlind study显示文摘 | Stopeck AT Lipton A Body J J | 2010 | J Olin Oncol2010，28，35： | 1 |
| 14 | Circulating tumor cells,disease progression,and survival in metastatic breast cancer显示文摘 | Cristofanilli M Budd G T Ellis M J Stopeck A Matera J Miller M C | 2004 | N Engl J Med2004，351，： | 1 |
| 15 | Results of a phase I dose- escalating study of the antiangiogenic agent,SU5416, in patients with advanced malignancies显示文摘 | Stopeck A Sheldon M Vahedian M | 2002 | Clin Cancer Res2002，8，9： | 1 |
| 16 | Diagnosing and treating breast cancer in elderly women : a call for improved understanding 显示文摘 | Downey L Livingston R Stopeck A | 2007 | J Am Geriatr Soc2007，55，10： | 1 |
| 17 | Phase II trial of the HSP90 inhibitor tanespimycin (Tan)+ trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)显示文摘 | Modi S Sugarman S Stopeck A | 2008 | J Clin Oncol2008，26，5： | 1 |
| 18 | Diagnosing and treating breastin elderly women:a call for improved understanding显示文摘 | Downey L Livingston R Stopeck A | 2007 | J Am Geriatr Soc2007，55，10： | 1 |
| 19 | Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive nonHodgkin′s lymphoma: correlative studies from the SWOG S0108 trial显示文摘 | Stopeck A Iannone M Rimsza L | 2004 | Blood (ASH Annual Meeting Abstracts)2004，104，： | 1 |
| 20 | Denosumab comparedwith zoledronic acid for the treatment of bone metastases in pa-tients with advanced breast cancer:a randomized,double-blindstudy显示文摘 | Stopeck AT Lipton A Body JJ | 2010 | J Clin Oncol2010，28，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员